Record ID | ia:platinumbaseddru0000unse |
Source | Internet Archive |
Download MARC XML | https://archive.org/download/platinumbaseddru0000unse/platinumbaseddru0000unse_marc.xml |
Download MARC binary | https://www.archive.org/download/platinumbaseddru0000unse/platinumbaseddru0000unse_meta.mrc |
LEADER: 07631cam 2201009Ma 4500
001 ocm49851575
003 OCoLC
005 20180718054554.0
008 020403s2000 njua ob 001 0 eng d
006 m o d
007 cr cn|||||||||
040 $aN$T$beng$epn$cN$T$dOCLCQ$dOCLCG$dOCLCQ$dE7B$dOCLCQ$dTUU$dOCLCQ$dTNF$dOCLCQ$dYDXCP$dCNTRU$dIDEBK$dOCLCE$dOCLCO$dOCLCF$dOCLCQ$dOCLCO$dGW5XE$dUA@$dOCLCQ$dEBLCP$dOCLCQ$dMWM$dOCLCO$dSUR$dUAB$dOCLCQ$dSAV$dQT7$dOCLCQ$dOCLCA$dLUE$dOCLCO
019 $a191037077$a533426420$a606284403$a646411932$a961574666$a962643612$a970749107$a984884786$a1001495971$a1004476863$a1004803276$a1005051113$a1007391865$a1008897019$a1013733055$a1017925316
020 $a0585395136$q(electronic bk.)
020 $a9780585395135$q(electronic bk.)
020 $a9781592590124$q(electronic bk.)
020 $a1592590128$q(electronic bk.)
020 $z0896035999$q(alk. paper)
020 $z9780896035997$q(alk. paper)
035 $a(OCoLC)49851575$z(OCoLC)191037077$z(OCoLC)533426420$z(OCoLC)606284403$z(OCoLC)646411932$z(OCoLC)961574666$z(OCoLC)962643612$z(OCoLC)970749107$z(OCoLC)984884786$z(OCoLC)1001495971$z(OCoLC)1004476863$z(OCoLC)1004803276$z(OCoLC)1005051113$z(OCoLC)1007391865$z(OCoLC)1008897019$z(OCoLC)1013733055$z(OCoLC)1017925316
042 $adlr
050 4 $aRC271.C5$b.P53 2000eb
060 4 $aQV 269 P716-2 2000
072 7 $aMED$x062000$2bisacsh
072 7 $aHEA$x039030$2bisacsh
082 04 $a616.99/4061$221
245 00 $aPlatinum-based drugs in cancer therapy /$cedited by Lloyd R. Kelland and Nicholas P. Farrell.
260 $aTotowa, N.J. :$bHumana Press,$c℗♭2000.
300 $a1 online resource (xii, 341 pages) :$billustrations.
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aCancer drug discovery and development ;$v7
504 $aIncludes bibliographical references and index.
506 $3Use copy$fRestrictions unspecified$2star$5MiAaHDL
533 $aElectronic reproduction.$b[S.l.] :$cHathiTrust Digital Library,$d2010.$5MiAaHDL
538 $aMaster and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.$uhttp://purl.oclc.org/DLF/benchrepro0212$5MiAaHDL
583 1 $adigitized$c2010$hHathiTrust Digital Library$lcommitted to preserve$2pda$5MiAaHDL
588 0 $aPrint version record.
520 $aIn Platinum-Based Drugs in Cancer Therapy, leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair, replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The antitumor activity and toxicology of platinum-based drugs is also addressed in a thorough discussion of the clinical experience with cisplatin and carboplatin, including their promising recent combinations with taxanes and oxaliplatin. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered. Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs. This important book captures the essence of the fresh clinical possibilities now strongly emerging thirty years after cisplatin's discovery.
505 0 $aI: Platinum Chemistry -- 1 The Chemistry of Cisplatin in Aqueous Solution -- 2 Chemistry and Structural Biology of 1,2-Interstrand Adducts of Cisplatin -- 3 Transplatin-Modified Oligonucleotides as Potential Antitumor Drugs -- II: Platinum Biochemistry -- 4 Cisplatin Accumulation -- 5 Cisplatin Resistance in Ovarian Cancer: Mismatch Repairand Engagement of Apoptosis -- 6 DNA Adduct Tolerance and Bypass -- 7 How Does Cisplatin Kill Cells? -- III: Clinical Antitumor Activity and Toxicology of Platinum Drugs -- 8 Clinical Experience with Cisplatin and Carboplatin -- 9 Clinical Experience: Platinum and Taxanes -- 10 Clinical Experience: DACH-Based Platinum Drugs -- 11 Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents -- 12 Toxicology and Regulatory Aspects of Platinum Drugs -- IV: New Platinum Drugs of the Future -- 13 New Platinum Drugs: The Pathway to Oral Therapy -- 14 Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm.
650 0 $aCancer$xChemotherapy.
650 6 $aCisplatine.
650 6 $aPlatine$xEmploi en the rapeutique.
650 6 $aCancer$xChimiothe rapie.
650 7 $aMEDICAL$xOncology.$2bisacsh
650 7 $aHEALTH & FITNESS$xDiseases$xCancer.$2bisacsh
650 7 $aAntine oplasiques.$2fmesh
650 7 $aCisplatine.$2fmesh
650 7 $aTumeurs$xTraitement me dicamenteux.$2fmesh
650 7 $aCompose s du platine$xusage the rapeutique.$2fmesh
650 7 $aCancer$xChemotherapy.$2fast$0(OCoLC)fst00845327
650 7 $aCarboplatine.$2ram
650 7 $aCisplatine.$2ram
650 7 $aOxaliplatine.$2ram
650 7 $aADN$xRe paration.$2ram
650 12 $aAntineoplastic Agents.
650 22 $aCisplatin.
650 22 $aNeoplasms$xdrug therapy.
650 22 $aPlatinum Compounds$xtherapeutic use.
655 4 $aElectronic books.
655 0 $aElectronic books.
700 1 $aFarrell, Nicholas,$d1948-
700 1 $aKelland, Lloyd R.
776 08 $iPrint version:$tPlatinum-based drugs in cancer therapy.$dTotowa, N.J. : Humana Press, ℗♭2000$z0896035999$w(DLC) 99032239
830 0 $aCancer drug discovery and development ;$v7.
856 40 $3ebrary$uhttp://site.ebrary.com/id/10181225
856 40 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=48040
856 40 $3Google$uhttp://books.google.com/books?id=V6VrAAAAMAAJ
856 40 $3HathiTrust Digital Library, Limited view (search only)$uhttp://catalog.hathitrust.org/api/volumes/oclc/41400894.html
856 40 $3MyiLibrary$uhttp://www.myilibrary.com?id=82009
856 40 $3SpringerLink$uhttp://dx.doi.org/10.1007/978-1-59259-012-4
856 40 $3SpringerLink$uhttp://link.springer.com/10.1007/978-1-59259-012-4
856 41 $3Table of contents$uhttp://catdir.loc.gov/catdir/enhancements/fy0825/99032239-t.html
856 42 $3Publisher description$uhttp://catdir.loc.gov/catdir/enhancements/fy0825/99032239-d.html
856 4 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=48040
856 40 $zClick for electronic text$uhttp://uiwtx.idm.oclc.org/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=48040
856 40 $uhttps://login.lacollegelibrary.idm.oclc.org/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=48040
938 $aEBL - Ebook Library$bEBLB$nEBL3036767
938 $aebrary$bEBRY$nebr10181225
938 $aEBSCOhost$bEBSC$n48040
938 $aYBP Library Services$bYANK$n2328054
938 $aYBP Library Services$bYANK$n2625924
029 1 $aAU@$b000056714670
029 1 $aNZ1$b15749770
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 672 OTHER HOLDINGS